About this trial
The purpose of this study is to examine the effects of different sedation drugs used for the awake fiberoptic intubation procedure. Benzodiazapines and narcotics (such as midazolam and fentanyl) are standard drugs used for sedation during awake fiberoptic intubation. Dexmedetomidine, midazolam, and fentanyl are approved by the Food and Drug Administration (FDA) procedural sedation. These drugs might be given to the patient regardless of their participation in the study.
In addition to midazolam and fentanyl study subjects will also receive either dexmedetomidine or a placebo (a salt solution that contains no drug). It is believed that dexmedetomidine will not slow down breathing as much as the combination of the valium-like drug and narcotic. In our study, we are trying to determine if this is the best drug for sedation during an awake fiberoptic procedure.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Subjects with potentially difficult airways who require awake fiberoptic intubations will be identified from the OR schedule and the pre-operative clinic workups.
Disqualifiers
Anyone who does not meet the inclusion criteria
Trial population
All adults with potentially difficult airways undergoing elective procedures will be eligible.
Trial design
Case-control
Prospective
Treatments tested in this trial
Dexmedetomidine
Drugdexmedetomidine, midazolam, and fentanyl (titrated to effect) to facilitate intubation
Treatment groups
Trial outcomes
Primary outcomes
Desaturation
Measurement using pulse oximetry (percent saturation)
Hemodynamic Lability
mm Hg
Dose of Fentanyl Used
mcg
Secondary outcomes
Patient overall experience assessed by VAS satisfaction.
Polling will be taken to measure patients' satisfaction with each sedation regiment on the scale from 1-10
Sponsors and contacts
Click on the lead sponsor to view all of their trials.